236 related articles for article (PubMed ID: 27393297)
1. Central serous chorioretinopathy in primary hyperaldosteronism.
van Dijk EH; Nijhoff MF; de Jong EK; Meijer OC; de Vries AP; Boon CJ
Graefes Arch Clin Exp Ophthalmol; 2016 Oct; 254(10):2033-2042. PubMed ID: 27393297
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
[TBL] [Abstract][Full Text] [Related]
3. Central serous chorioretinopathy in active endogenous Cushing's syndrome.
Brinks J; van Haalen FM; van Rijssen TJ; Biermasz NR; Meijer OC; Pereira AM; Boon CJF; van Dijk EHC
Sci Rep; 2021 Feb; 11(1):2748. PubMed ID: 33531597
[TBL] [Abstract][Full Text] [Related]
4. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.
Kim YK; Ryoo NK; Woo SJ; Park KH
Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629
[TBL] [Abstract][Full Text] [Related]
5. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy.
Jirarattanasopa P; Ooto S; Tsujikawa A; Yamashiro K; Hangai M; Hirata M; Matsumoto A; Yoshimura N
Ophthalmology; 2012 Aug; 119(8):1666-78. PubMed ID: 22521082
[TBL] [Abstract][Full Text] [Related]
6. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Furuta M; Sekiryu T
Retina; 2011 Oct; 31(9):1921-7. PubMed ID: 21878850
[TBL] [Abstract][Full Text] [Related]
7. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
[TBL] [Abstract][Full Text] [Related]
8. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.
Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F
Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720
[TBL] [Abstract][Full Text] [Related]
9. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration.
Fung AT; Yannuzzi LA; Freund KB
Retina; 2012 Oct; 32(9):1829-37. PubMed ID: 22850219
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
[TBL] [Abstract][Full Text] [Related]
11. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
[TBL] [Abstract][Full Text] [Related]
12. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional configuration of subretinal fluid in central serous chorioretinopathy.
Ahn SE; Oh J; Oh JH; Oh IK; Kim SW; Huh K
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):5944-52. PubMed ID: 23920371
[TBL] [Abstract][Full Text] [Related]
14. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
15. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
Pryds A; Larsen M
Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096
[TBL] [Abstract][Full Text] [Related]
16. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
[TBL] [Abstract][Full Text] [Related]
17. Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy.
Hamzah F; Shinojima A; Mori R; Yuzawa M
BMC Ophthalmol; 2014 Nov; 14():145. PubMed ID: 25421855
[TBL] [Abstract][Full Text] [Related]
18. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
19. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
[TBL] [Abstract][Full Text] [Related]
20. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F
Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
